PT  - JOURNAL ARTICLE
AU  - TOYA, RYO
AU  - WATAKABE, TAKAHIRO
AU  - MURAKAMI, DAIZO
AU  - MATSUYAMA, TOMOHIKO
AU  - SAITO, TETSUO
AU  - FUKUGAWA, YOSHIYUKI
AU  - NISHIMOTO, KOHEI
AU  - ORITA, YORIHISA
AU  - OYA, NATSUO
TI  - Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation
AID  - 10.21873/anticanres.15474
DP  - 2022 Jan 01
TA  - Anticancer Research
PG  - 205--209
VI  - 42
IP  - 1
4099  - http://ar.iiarjournals.org/content/42/1/205.short
4100  - http://ar.iiarjournals.org/content/42/1/205.full
SO  - Anticancer Res2022 Jan 01; 42
AB  - Background/Aim: We retrospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) for T3 N0 glottic carcinoma without vocal cord fixation. Patients and Methods: Twenty-five patients underwent TPF-CCRT without elective nodal irradiaion (ENI). After the RT of 40 Gy, five patients (20%) without tumor regression underwent surgery. Others underwent RT with a median total dose of 66 Gy. Results: Of the five patients who underwent surgery after the RT of 40 Gy, two showed residual carcinoma pathologically and the other three were confirmed to have complete pathological response to the treatment. The 5-year local control rate was 87%. No patients exhibited regional failure. No acute toxicities of grade 5 or late toxicities ≥grade 3 were observed. Conclusion: TPF-CCRT provides excellent tumor control with acceptable toxicities. CCRT while omitting ENI is a reasonable approach for T3 N0 glottic carcinoma without vocal cord fixation.